Fig. 3From: Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysisScatter plot of incremental cost-effectiveness ratios for 10 pharmacologic combination strategies. DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1Back to article page